GSK seeks Japanese approval for umeclidinium monotherapy to treat COPD

Posted on Updated on

GlaxoSmithKline plc has submitted a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), administered using the Ellipta dry powder inhaler.

The New Drug Application has been submitted to the MHLW for UMEC monotherapy (62.5mcg), as a once-daily inhaled dry powder maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

UMEC has recently been granted market authorisation in the US, Canada and in Europe, with the approved trade name Incruse Ellipta. Regulatory filings in other countries will take place throughout 2014 and onwards.

UMEC is not currently approved in Japan and is not licensed anywhere outside of the US, Canada and the European Union.

Incruse and Ellipta are trademarks of the GlaxoSmithKline group of companies.

Source: PharmaBiz


Let us know what you think!

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s